Senseonics Holdings, Inc. · NASDAQ:SENS
Senseonics — Investor Presentation (May 2022)
18 slides from Senseonics's investor presentation, May 2022
Slide 1: Eversense E3 CGM System
® Eversense E3 CGM System The world’s FIRST and ONLY long-term Continuous Glucose Monitoring System Tim Goodnow, PhD Corporate Presentation President and CEO May 2022 © 2021 Senseonics™ Corporate Presentation, updated November 2021 1
Slide 2: Forward-Looking Statements
FORWARD-LOOKING STATEMENTS This presentation, including the remarks of management contains forward-looking statements, as defined in the Private Securities Litigation Reform Act of 1995, statements regarding managements plans, objectives and goals for future operations, including preliminary targets
Slide 3: Our Mission
OUR MISSION To transform lives in the global diabetes community with differentiated, long-term implantable glucose management technology. © 2021 Senseonics™ Corporate Presentation, updated November 2021 3
Slide 4: Corporate Overview and Milestones
CORPORATE OVERVIEW AND MILESTONES The FIRST and ONLY long-term and implantable CGM System. Available by prescription in US and select markets in Europe. Proven technology with rich development history, regulatory approvals and commercial accomplishments. 2016-2017 2018 2019 2020 2021 2022 Feb. 1 OUS
Slide 5: High Growth Market $14B+
HIGH GROWTH MARKET CGM Fastest Growing Diabetes Technology Segment Globally* ~ 37% CAGR $14B+ Annual US Market Opportunity *Estimates for top 4 CGM companies (Dexcom, Abbott, Medtronic and Senseonics), based upon available publicly stated guidance, historic performance, and external CGM market mode
Slide 6: Significant Unmet Need Among BGM/CGM Users
SIGNIFICANT UNMET NEED AMONG BGM/CGM USERS Why BGM users won't adopt CGM1 Most desired CGM improvements2 Longer Sensor Wear Better Accuracy 59% 31% Dexcom Medtronic Abbott 35% 44% 1 Market Segmentation Research June 2019 dQ&A CGM US Patient Survey Q3 2020 2 dQ&A CGM US Patient Survey Q3 2020 © 2021
Slide 7: Eversense E3 CGM System: The First and Only
Eversense E3 CGM System addresses unmet needs as THE FIRST AND ONLY ▪ CGM that lasts for 6 months vs. days ▪ Fully implantable 3 rd generation sensor ▪ Long Duration CGM achieves 8.5% MARD ▪ Transmitter that is removable ▪ System with on-body vibe alerts for hypo and hyper warnings ▪ System with fre
Slide 8: Eversense US Patient Profiles
1 EVERSENSE US PATIENT PROFILES Broad appeal of Eversense with new and existing CGM users Target patient profiles Where Eversense users Usage split evenly across age come from groups ▪ Dissatisfied with Current CGM ▪ New to CGM with Reason ▪ Gateway (Libre) Top preferred features of existing users ▪
Slide 9: Proven Top-Tier Accuracy in PROMISE Study
1 PROVEN TOP-TIER ACCURACY IN PROMISE STUDY MARD: 8.5% Exceptional Performance for Duration of 180 Days ▪ Prospective multi-center pivotal trial at 8 sites in Accurate and stable for 6 months Highly accurate – particularly the US for new 180-day sensor in low range Percent of readings within 15 mg/d
Slide 10: Strong & Expanding Reimbursement
STRONG & EXPANDING REIMBURSEMENT Transitioning Commercial and Medicare coverage for 200 million lives to 180-day coverage Medicare National Coverage ▪ Therapeutic CGM Indication ▪ Part B Medical Services ▪ CMS National Payment Rate ▪ Providers bill Medicare directly with existing CPT codes to includ
Slide 11: Commercial Collaboration with Ascensia
COMMERCIAL COLLABORATION WITH ASCENSIA ▪ Broad Partnership Features Global Commercialization and Financing Arrangements with Leader in BGM ▪ ASCENSIA is the Exclusive Worldwide Distribution Partner for Eversense® E3, Eversense® XL and Future Generation Products ▪ Senseonics to Focus Streamlined Oper
Slide 12: Eversense Pipeline
EVERSENSE PIPELINE © 2021 Senseonics™ Corporate Presentation, updated November 2021 1212
Slide 13: Product Vision
PRODUCT VISION Uniquely differentiated long-term technology solution with multiple product configurations SENSOR All Diabetes Patient Segments NO sensor change for 1 year NO daily calibration required NO transmitter on body For Type 1 and Type 2 Patients On Demand and Continuous Monitoring NOTE: Pro
Slide 14: Senseonics Product Pipeline
SENSEONICS PRODUCT PIPELINE 2016 - 2021 2022 - 2025 Eversense CGM 180D CGM BGM Connectivity 365D CGM (Rome) 90-day CGM system E3 sensor with advanced Direct communication with One year sensor for chemistry and features Ascensia Contour Meter continuous readings, 1 cal/week Eversense XL CGM 180-day
Slide 15: Eversense 365 System
EVERSENSE 365 SYSTEM One annual sensor for use – CGM for peace of mind and FGM for discretion TECHNOLOGY Gen 2 sensor platform (Rome); array-based sensing USE CASE Full year use with 1 sensor and 1 cal/week TARGET Intensively managed patients who want better control + All insulin-using patients NOTE
Slide 16: Freedom System
FREEDOM SYSTEM Autonomous sensor testing with data processing capacity enabling 2 products from 1 platform TECHNOLOGY Enhanced Rome 2 sensor with integrated battery; updated algorithm USE CASE Full year use with 1 sensor and 1 cal/week Two unique products: 1. CGM with transmitter/FGM without transmi
Slide 17: © 2021 Senseonics™ Corporate Presentation, updated November 2021
© 2021 Senseonics™ Corporate Presentation, updated November 2021 17
Slide 18: Thank You
THANK YOU © 2021 Senseonics™ Corporate Presentation, updated November 2021 18
Senseonics Holdings — Investor Presentation (May 2022) on 6ix